Brownstein, M.J.; Simon, N.G.; Long, J.D.; Yankey, J.; Maibach, H.T.; Cudkowicz, M.; Coffey, C.; Conwit, R.A.; Lungu, C.; Anderson, K.E.;
et al. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial. J. Clin. Med. 2020, 9, 3682.
https://doi.org/10.3390/jcm9113682
AMA Style
Brownstein MJ, Simon NG, Long JD, Yankey J, Maibach HT, Cudkowicz M, Coffey C, Conwit RA, Lungu C, Anderson KE,
et al. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial. Journal of Clinical Medicine. 2020; 9(11):3682.
https://doi.org/10.3390/jcm9113682
Chicago/Turabian Style
Brownstein, Michael J., Neal G. Simon, Jeffrey D. Long, Jon Yankey, Hilda T. Maibach, Merit Cudkowicz, Christopher Coffey, Robin A. Conwit, Codrin Lungu, Karen E. Anderson,
and et al. 2020. "Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial" Journal of Clinical Medicine 9, no. 11: 3682.
https://doi.org/10.3390/jcm9113682
APA Style
Brownstein, M. J., Simon, N. G., Long, J. D., Yankey, J., Maibach, H. T., Cudkowicz, M., Coffey, C., Conwit, R. A., Lungu, C., Anderson, K. E., Hersch, S. M., Ecklund, D. J., Damiano, E. M., Itzkowitz, D. E., Lu, S., Chase, M. K., Shefner, J. M., McGarry, A., Thornell, B.,
... Drazinic, C.
(2020). Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial. Journal of Clinical Medicine, 9(11), 3682.
https://doi.org/10.3390/jcm9113682
